GH Research PLC
NASDAQ:GHRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
UMH Properties Inc
NYSE:UMH
|
US |
|
Liberty Media Corp
NASDAQ:FWONA
|
US |
|
RTL Group SA
XETRA:RRTL
|
LU |
GH Research PLC
Other Items
GH Research PLC
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Other Items
$46.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Other Items
$18m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Other Items
-$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Other Items
$25.7m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Other Items
€55.9m
|
CAGR 3-Years
84%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GH Research PLC
Glance View
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.
See Also
What is GH Research PLC's Other Items?
Other Items
46.3m
USD
Based on the financial report for Dec 31, 2025, GH Research PLC's Other Items amounts to 46.3m USD.
What is GH Research PLC's Other Items growth rate?
Other Items CAGR 1Y
-29%
Over the last year, the Other Items growth was -29%.
